中文摘要：

目的采用Meta分析的方法定量评价碳离子治疗前列腺癌的有效性。方法检索PubMed、Cochranel ibrary、EMBASE、中国期刊全文数据库、中国生物医学文献数据库、万方数据库，同时追溯纳入研究的参考文献，收集碳离子治疗前列腺癌的临床试验，提取数据，检索时限均为建库至2015年12月。采用MetaAnalyst Beta3．13和STATA12．0进行Meta分析。结果共纳入6个研究（8个临床试验），Meta分析结果显示，3、4、5和8年的总生存率分别为95．7％、90．9％、91．8％和83．9％，4年和5年肿瘤特异生存率分别为97．1％和97．6％，4、5和8年无生化复发率分别为88％、86．3％和79．1％，3、4和5年的局部控制率分别为98．1％、97．1％和98．4％，总死亡率、前列腺癌死亡率和并发症死亡率分别为7％、2．4％和7％。不同T分期对5年总生存率、无生化复发率和肿瘤特异生存率产生影响。结论碳离子是一种安全、有效、可行的前列腺癌治疗方法，具有临床应用的前景，但是否优于其他放射治疗，尚需在前列腺癌患者中进行高质量前瞻性、随机对照临床研究。

英文摘要：

Objective To evaluate the efficacy of the carbon ion radiotherapy for prostate cancer by Meta-analysis. Methods We searched the Cochrane library, PubMed, EMBASE, China Journal Fulltext Database, Chinese Biomedical Database, and Wanfang Database from their inception to December 2015, in order to collect clinical trial data of carbon ion radiotherapy for prostate cancer. References included within these studies were also retrieved. Meta-analysis was performed using MetaAnalyst Beta 3. 13 and STATA 12.0 software. Results Six studies （eight clinical trials） were included. The results of Meta-analysis show that, the overall survival rates of 3,4,5 and 8 years were 95.7% , 90.9% , 91.8% and 83.9% , respectively. The cause specific survival rate of 4 and 5 years were 97. 1% and 97.6% . The bNED rate of 3,4,5 and 8 years were 88% , 86.3% and 79. 1% , respectively. The local control rates of 3, 4 and 5 years were 98. 1% , 97. 1% and 98.4% , respectively. The rate of total death, prostate cancer death and intereurrent death were 7% , 2.4% and 7% , respectively. Different T-stage may affect the fiveyear of overall survival rate, bNED rate and cause specific survival rate. Conclusions The current evidence shows that carbon ion radiotherapy in general is a feasible treatment for prostate cancer, whether carbon ion is better than other radiotherapy, prospective, randomized, controlled clinical trial to get more evidence is required for carbon ion radiotherapy versus standard treatment for prostate cancer patients.